

AstraZeneca Docket No. 100829-1P US

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

Application of: **Peter Bernstein et al.**  
International Application Number: **PCT/SE2003/001399**  
International Filing Date: **September 8, 2003**  
For: **NAPHTHYL ETHER COMPOUNDS AND THEIR USE**  
Group Art Unit: **Not yet allocated**  
Examiner: **Not yet allocated**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications which they believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

The references listed on the attached Form PTO/SB/08a and PTO/SB/08b were cited by the Examiner in the International Search Report.

This Information Disclosure Statement is being filed within three months of the filing of the application. Accordingly, no fee is required for consideration of the references filed herewith.

Respectfully submitted,

Dated: March 8, 2005

By: 

Kenneth F. Mitchell, Ph.D.  
Attorney for Applicants  
Reg. No. 42,007  
Telephone: 302/886-7466

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

*(Use as many sheets as necessary)*

Sheet

1

of

1

Application Number

IA No. PCT/SE2003/01399

Filing Date

Intl Filing Date 9/8/2003

First Named Inventor

Peter BERNSTEIN

**Art Unit**

Examiner Name

Attorney Docket Number

100829-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		GB 2347423 A	09/06/2000	Merck Sharp & Dohme	clms 8, 16-18, pg 38, ln 23-26	
		WO 9519344 A1	07/20/1995	Merck Sharp & Dohme	the claims, pg 18, ln 12 - pg 19, ln 20	
		WO 9410165 A1	05/11/1994	Merck Sharp & Dohme	the claims, pg 20, ln 16 - pg 21, ln 29	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b> <b>10/527280</b> Application Number IA NO. PCT/SE2003/001399 Filing Date Intl. Filing Ssept. 8, 2003 First Named Inventor Peter BERNSTEIN Art Unit Examiner Name Attorney Docket Number 100829-1P US	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)					
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GRAEME I. STEVENSON ET AL, "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist," J. Med. Chem., Vol. 38 ( No. 8), p. 1264-1266, (1995).	
		GRAEME I. STEVENSON ET AL, "4,4 Disubstituted Piperidine High-Affinity NK1, Antagonists: Structure-Activity Relationships and in Vivo Activity," J. Med. Chem., Vol. 41 ( No. 23), p. 4623-4635, (November 23, 1998).	
		JASON M. ELLIOTT ET AL, "4,4-Disubstituted Cyclohexylamine NK1 Receptor Antagonists I," Bioorganic & Medicinal Chemistry Letters, Vol. 12 ( No. 13), p. 1755-1758, table 3, compound nos. 23, 27 (July 8, 2002).	
		THOMAS RYCKMANS ET AL, "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants," Bioorganic & Medicinal Chemistry Letters, Vol. 12 ( No. 2), p. 261-264, (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.